<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6831721/results/search/disease/results.xml">
  <result pre="States[], 2Innovative Genomics InstituteBerkeley, CAUnited States[], 3Section of Cell and" exact="Developmental" post="Biology, University of CaliforniaSan Diego, CAUnited States[], 4Tata Institute"/>
  <result pre="not comply with these terms. Abstract While efforts to control" exact="malaria" post="with available tools have stagnated, and arbovirus outbreaks persist"/>
  <result pre="persist around the globe, the advent of clustered regularly interspaced" exact="short" post="palindromic repeat (CRISPR)-based gene editing has provided exciting new"/>
  <result pre="In one such strategy, called &quot;population replacement&quot;, mosquitoes, and other" exact="disease" post="vectors are engineered with effector genes that render them"/>
  <result pre="we review the disease-refractory genes designed to date to target" exact="Plasmodium falciparum malaria" post="transmitted by Anopheles gambiae, and arboviruses transmitted by Aedes"/>
  <result pre="the disease-refractory genes designed to date to target Plasmodium falciparum" exact="malaria" post="transmitted by Anopheles gambiae, and arboviruses transmitted by Aedes"/>
  <result pre="these effector genes, and genetic approaches to prevent parasite and" exact="viral" post="escape variants. One general approach is to increase the"/>
  <result pre="the target product profile for population replacement strategies for vector-borne" exact="disease" post="control. This differs between early phase field trials and"/>
  <result pre="control. This differs between early phase field trials and wide-scale" exact="disease" post="control. In the latter case, the demands on effector"/>
  <result pre="effector genes in the upcoming evolutionary tug-of-war. clustered regularly interspaced" exact="short" post="palindromic repeats clustered regularly interspaced short palindromic repeats–associated protein"/>
  <result pre="tug-of-war. clustered regularly interspaced short palindromic repeats clustered regularly interspaced" exact="short" post="palindromic repeats–associated protein 9 gene drive homing malaria dengue"/>
  <result pre="regularly interspaced short palindromic repeats–associated protein 9 gene drive homing" exact="malaria" post="dengue Zika Funding Defense Sciences Office, DARPA10.13039/100006502 fig-count: table-count:"/>
  <result pre="Lee et al., 2019). The advent of clustered regularly interspaced" exact="short" post="palindromic repeat (CRISPR)-based gene editing (Doudna and Charpentier, 2014)"/>
  <result pre="Li et al., 2019) and of effector genes to target" exact="malaria" post="parasites (Carballar-Lejarazú and James, 2017), several dengue virus (DENV)"/>
  <result pre="al., 2006; Yen et al., 2018; Buchman et al., 2019a)," exact="chikungunya" post="(CHIKV) (Yen et al., 2018), and Zika (ZIKV) (Buchman"/>
  <result pre="understudied evolutionary tug-of-war between the anti-pathogen effector and pathogen evolution." exact="Resistance" post="can evolve against the gene drive technologies that support"/>
  <result pre="review the disease-refractory effectors designed to date to target the" exact="malaria" post="parasite Plasmodium falciparum transmitted by Anopheles gambiae, and arboviruses"/>
  <result pre="pathogen resistance in response to synthetic antipathogen effectors have been" exact="limited" post="to the laboratory, and conducted only over small time"/>
  <result pre="and conducted only over small time scales. Consequently, there is" exact="limited" post="direct evidence for resistance to these technologies in the"/>
  <result pre="product profile (TPP) for gene drive systems intended for vector-borne" exact="disease" post="control, with emphasis on the time span that the"/>
  <result pre="functional in the vector population. Lessons From the Evolution of" exact="Resistance" post="to Antimalarial Drugs Antimalarial drugs provide a well-studied example"/>
  <result pre="effector genes present and synthetic elements included on the construct." exact="Resistance" post="to antimalarial drugs has been documented several times over"/>
  <result pre="1930s, was quickly adopted for widespread treatment and prevention of" exact="malaria" post="caused by P. falciparum, Plasmodium vivax, and other species."/>
  <result pre="malaria caused by P. falciparum, Plasmodium vivax, and other species." exact="Resistance" post="of P. falciparum to the drug was first documented"/>
  <result pre="(Haldar et al., 2018). Table 1 Origins of resistance in" exact="malaria" post="parasite, Plasmodium falciparum, to monotherapy drugs. Monotherapy application dates"/>
  <result pre="to monotherapy drugs. Monotherapy application dates Drug and its mechanism" exact="Resistance" post="and its mechanism ∼1930–1950 Chloroquine interferes with the detoxification"/>
  <result pre="the parasite and to interfere with the detoxification of heme." exact="Resistance" post="to piperaquine quickly evolved in nature, and the drug"/>
  <result pre="for use in combination with artemisinin (Davis et al., 2005)." exact="Resistance" post="to this combination has recently emerged in western Cambodia,"/>
  <result pre="traditional medicine in the 1970s, has been used to treat" exact="malaria" post="for decades. Use of the drug as a monotherapy"/>
  <result pre="and amodiaquine) that are effective and well tolerated in patients." exact="Resistance" post="to artemisinin-based combination therapy drugs (ACTs) was first reported"/>
  <result pre="Curiously, resistance to ACTs has only been observed to a" exact="limited" post="extent in SSA, where the malaria burden is greatest."/>
  <result pre="been observed to a limited extent in SSA, where the" exact="malaria" post="burden is greatest. One possible explanation is that there"/>
  <result pre="greatest. One possible explanation is that there are many untreated" exact="malaria" post="infections in SSA—some symptomatic, but many asymptomatic. If drug"/>
  <result pre="One possible explanation is that there are many untreated malaria" exact="infections" post="in SSA—some symptomatic, but many asymptomatic. If drug resistance"/>
  <result pre="cost could outweigh the benefits in a scenario where many" exact="infections" post="go untreated. Treatment with &quot;weaker&quot; drugs is common in"/>
  <result pre="to evolve. In sum, these observations suggest that: i) the" exact="malaria" post="parasite P. falciparum has evolved resistance to a range"/>
  <result pre="evolutionary hurdle for the emergence of resistance. Malaria-Refractory Genes and" exact="Resistance" post="Concerns The malaria life cycle is complex and antimalarial"/>
  <result pre="the emergence of resistance. Malaria-Refractory Genes and Resistance Concerns The" exact="malaria" post="life cycle is complex and antimalarial effector genes could"/>
  <result pre="particularly attractive target, as it represents a population bottleneck for" exact="malaria" post="parasites in the mosquito. The most effective antimalarial effector"/>
  <result pre="1 Schematic of the life cycle of Plasmodium falciparum. The" exact="complete" post="life cycle takes place in two organisms: Anopheles mosquitoes"/>
  <result pre="takes place in two organisms: Anopheles mosquitoes and humans. A" exact="female" post="mosquito ingests micro- and macro-gametocytes (I) in blood from"/>
  <result pre="mosquito ingests micro- and macro-gametocytes (I) in blood from an" exact="infectious" post="human, which then fuse into diploid zygotes (II). Zygotes"/>
  <result pre="takes 10–18 days (the extrinsic incubation period). When an infected" exact="female" post="mosquito feeds again, sporozoites are released with saliva into"/>
  <result pre="(VII). This starts cycles of synchronous erythrocyte infection/rupture typical of" exact="malaria" post="fever (VIII). Some merozoites develop into gametocytes (IX), which"/>
  <result pre="develop into gametocytes (IX), which can be ingested by a" exact="female" post="mosquito, and the cycle begins again. Malaria-refractory genes and"/>
  <result pre="again. Malaria-refractory genes and other putative effector strategies to target" exact="malaria" post="parasites at various developmental stages are reviewed by Carballar-Lejarazu"/>
  <result pre="cellular melanization mechanisms that occur in nature and inactivate the" exact="malaria" post="parasite by encapsulating it in the midgut (Yassine et"/>
  <result pre="Any refractory gene aiming to interrupt the development of the" exact="malaria" post="parasite places a strong selective pressure on parasites capable"/>
  <result pre="the mosquito taking a blood meal. Melanization-based mechanisms that inactivate" exact="malaria" post="parasites exist in nature, as do resistant mechanisms in"/>
  <result pre="al. have documented a mechanism whereby two key regulators of" exact="malaria" post="melanization in An. gambiae (TEP1 and CLIPA8) are deactivated"/>
  <result pre="these could prevent sporozoites from entering the salivary glands at" exact="infection" post="levels encountered in natural conditions (Isaacs et al., 2012)."/>
  <result pre="conditions (Isaacs et al., 2012). However, in the laboratory, higher-than-normal" exact="parasitemia" post="resulted in some parasites reaching the salivary glands despite"/>
  <result pre="and produce higher loads, with potentially detrimental consequences for human" exact="disease" post="burden and transmission. Clearly, in the presence of anti-parasite"/>
  <result pre="and transmission. Clearly, in the presence of anti-parasite effector genes," exact="malaria" post="parasites displaying resistant phenotypes will be selected for in"/>
  <result pre="Development and Vector-Virus Interaction Studies Besides malaria, the largest vector-borne" exact="disease" post="burden is that due to the family of arboviruses"/>
  <result pre="these viruses. This leads to a dynamic population of mutant" exact="viral" post="genomes, referred to as a quasispecies, that can rapidly"/>
  <result pre="Andino and Domingo, 2015). At any point in time, the" exact="viral" post="population could comprise one or more variants that have"/>
  <result pre="confounded the development of antiviral drugs for many important human" exact="viral" post="infections. For example, due to the high mutation frequency"/>
  <result pre="example, due to the high mutation frequency of the human" exact="immunodeficiency" post="virus (HIV), a multi-target combinational drug approach is required"/>
  <result pre="required to minimize HIV replication. This approach typically targets the" exact="viral" post="reverse transcriptase (RT) gene, or other essential viral genes"/>
  <result pre="targets the viral reverse transcriptase (RT) gene, or other essential" exact="viral" post="genes with reasonably high genetic or structural conservation (Ceccherini-Silberstein"/>
  <result pre="not strictly comparable, this example demonstrates that targeting multiple essential" exact="viral" post="genes and conserved sites in the viral genome, the"/>
  <result pre="targeting multiple essential viral genes and conserved sites in the" exact="viral" post="genome, the common approach taken to mitigate antiviral effector"/>
  <result pre="considerations. For instance, a multi-target approach did not prevent rapid" exact="viral" post="resistance to ribavirin (Pfeiffer and Kirkegaard, 2003; Vignuzzi et"/>
  <result pre="RNA viruses at multiple sites and time points during the" exact="viral" post="replication cycle (Crotty et al., 2001; Crotty et al.,"/>
  <result pre="have evolved numerous systemic, small RNA-mediated immune defense mechanisms against" exact="viral" post="infections that drive adaptation of viral counter-defenses. Notably, viral-associated"/>
  <result pre="evolved numerous systemic, small RNA-mediated immune defense mechanisms against viral" exact="infections" post="that drive adaptation of viral counter-defenses. Notably, viral-associated immune"/>
  <result pre="immune defense mechanisms against viral infections that drive adaptation of" exact="viral" post="counter-defenses. Notably, viral-associated immune suppression has been identified in"/>
  <result pre="(Xia et al., 2018; Zheng et al., 2018). Presumably, similar" exact="viral" post="counter-defenses could be developed against antiviral effectors. In prominent"/>
  <result pre="viral counter-defenses could be developed against antiviral effectors. In prominent" exact="disease" post="vectors, such as Ae. aegypti, the immune response is"/>
  <result pre="prevent the replication and dissemination of arboviruses, and consequently allows" exact="systemic" post="infections that lead to arboviral transmission to vertebrate hosts."/>
  <result pre="the replication and dissemination of arboviruses, and consequently allows systemic" exact="infections" post="that lead to arboviral transmission to vertebrate hosts. One"/>
  <result pre="enhance natural mosquito immunity. Another approach could be to circumvent" exact="viral" post="evasion mechanisms in order to support viral clearance (Li"/>
  <result pre="be to circumvent viral evasion mechanisms in order to support" exact="viral" post="clearance (Li and Ding, 2006). The rapid mutation rates"/>
  <result pre="to their broad host tropism. Host-specific selection pressure can constrain" exact="viral" post="diversity (Weaver et al., 1992; Coffey et al., 2008;"/>
  <result pre="early will have the advantage of targeting smaller, less diverse" exact="viral" post="populations, and hence viral resistance will be slower to"/>
  <result pre="advantage of targeting smaller, less diverse viral populations, and hence" exact="viral" post="resistance will be slower to emerge. However, these viral"/>
  <result pre="hence viral resistance will be slower to emerge. However, these" exact="viral" post="populations rapidly diversify in the vector given their high"/>
  <result pre="2007; Tsetsarkin and Weaver, 2011) and can initiate or amplify" exact="disease" post="outbreaks (Feng et al., 2019), as seen in the"/>
  <result pre="et al., 2007). As the virus disseminates in the mosquito," exact="viral" post="diversity may be further bottlenecked (Patterson et al., 2018)"/>
  <result pre="effector strategies may be able to take advantage of the" exact="lower" post="viral diversity at these later bottlenecks in the transmission"/>
  <result pre="strategies may be able to take advantage of the lower" exact="viral" post="diversity at these later bottlenecks in the transmission cycle."/>
  <result pre="of these viruses, and effectors that disrupt areas of the" exact="viral" post="genome required for host switching could further limit their"/>
  <result pre="effectors. Studying these important vector-virus interactions and their role in" exact="viral" post="evolution will support the design of new and more"/>
  <result pre="development and future directions for these effectors. Arbovirus-Refractory Genes and" exact="Resistance" post="Concerns The majority of arbovirus-refractory effectors developed to date"/>
  <result pre="serve as small interfering RNAs (siRNAs) capable of targeting the" exact="viral" post="genome and consequently suppressing viral replication and transmission (Franz"/>
  <result pre="(siRNAs) capable of targeting the viral genome and consequently suppressing" exact="viral" post="replication and transmission (Franz et al., 2006; Travanty et"/>
  <result pre="homozygotes being completely refractory to ZIKV infection, and heterozygotes having" exact="infection" post="and transmission rates low enough to make them unlikely"/>
  <result pre="based on small RNAs, and to prevent the evolution of" exact="viral" post="escape variants, high target coverage of the viral genome"/>
  <result pre="evolution of viral escape variants, high target coverage of the" exact="viral" post="genome is required. Indeed, some viruses have been shown"/>
  <result pre="et al., 2014), and engineering efforts must ensure that high" exact="viral" post="replication is not an evolutionary consequence. The rigorous target"/>
  <result pre="of escape mutants. An RNAi-mediated effector itself may also increase" exact="viral" post="genetic diversity thereby potentiating viral escape. For example, the"/>
  <result pre="effector itself may also increase viral genetic diversity thereby potentiating" exact="viral" post="escape. For example, the RNAi immune response drove the"/>
  <result pre="so, what the impact of this diversification would be on" exact="viral" post="resistance. It is also still an open question as"/>
  <result pre="as to how many small RNAs are necessary to prevent" exact="viral" post="escape mutants in a diverse wild population, and the"/>
  <result pre="population, and the potential effect of this RNAi-mediated approach on" exact="viral" post="evolution. A recent approach taken to target multiple serotypes"/>
  <result pre="utilized a broadly neutralizing scFV (Buchman et al., 2019a), reducing" exact="viral infection" post="and dissemination of all four major serotypes of DENV."/>
  <result pre="a broadly neutralizing scFV (Buchman et al., 2019a), reducing viral" exact="infection" post="and dissemination of all four major serotypes of DENV."/>
  <result pre="to increase the number of sites being targeted in the" exact="viral" post="genome. This was used by Mishra et al. (2016)"/>
  <result pre="must consider the high mutation rate and large size of" exact="viral" post="populations, or viral &quot;quasispecies&quot;, and the implications of these"/>
  <result pre="high mutation rate and large size of viral populations, or" exact="viral" post="&quot;quasispecies&quot;, and the implications of these features on viral"/>
  <result pre="or viral &quot;quasispecies&quot;, and the implications of these features on" exact="viral" post="resistance to effector genes. That said, off-target effects of"/>
  <result pre="the risk of escape mutants, despite the heightened diversity of" exact="viral" post="quasispecies (Yen et al., 2018). Taken together, arboviruses and"/>
  <result pre="effector genes clearly have distinct properties as compared to the" exact="malaria" post="parasites and antimalarial effectors; however the critical related question"/>
  <result pre="how we can substantially delay the emergence and spread of" exact="viral" post="escape mutants. Delaying and Managing Resistance to Disease-Refractory Genes"/>
  <result pre="emergence and spread of viral escape mutants. Delaying and Managing" exact="Resistance" post="to Disease-Refractory Genes Strategies for delaying and managing resistance"/>
  <result pre="is to prevent selection of escape mutants with a higher" exact="viral" post="or parasitic load. This must be true across the"/>
  <result pre="similar scale. Figure 2 Potential intervention points to block mosquito-borne" exact="disease" post="transmission. Mosquito-borne diseases require incubation periods in both mosquito"/>
  <result pre="hosts. Blocking the cycle at any point will interrupt transmission." exact="Multiple" post="coordinated interventions will likely be needed to achieve effective"/>
  <result pre="interventions will likely be needed to achieve effective and sustainable" exact="disease" post="control. Potential interventions that could be implemented on the"/>
  <result pre="blocking one or more of the steps required for pathogen" exact="infection" post="and/or dissemination in mosquitoes. For Plasmodium parasites (I) and"/>
  <result pre="or more essential points in the pathogen replication cycle: (A)—initial" exact="infection" post="of a midgut epithelial cell; (B)—spread of infection among"/>
  <result pre="in the pathogen replication cycle: (A)—initial infection of a midgut" exact="epithelial" post="cell; (B)—spread of infection among midgut epithelial cells; (C)—midgut"/>
  <result pre="cycle: (A)—initial infection of a midgut epithelial cell; (B)—spread of" exact="infection" post="among midgut epithelial cells; (C)—midgut escape of infecting agents"/>
  <result pre="of a midgut epithelial cell; (B)—spread of infection among midgut" exact="epithelial" post="cells; (C)—midgut escape of infecting agents from midgut epithelial"/>
  <result pre="midgut epithelial cells; (C)—midgut escape of infecting agents from midgut" exact="epithelial" post="cells into hemolymph; (D)—salivary gland infection, and (E)—salivary gland"/>
  <result pre="and are expectorated in a subsequent blood meal of the" exact="female" post="mosquito, respectively. If any one or more of these"/>
  <result pre="the vertebrate, purifying selection reduces the genetic diversity of viruses" exact="acquired" post="during blood feeding (1), but with the high mutation"/>
  <result pre="Effectors that target the virus in the early stages of" exact="infection" post="(A and early B) prior to expansion and diversification"/>
  <result pre="provides an additional rationale for maintaining an integrated vector and" exact="disease" post="control program. The simple rationale is that, if the"/>
  <result pre="form of population suppression (Carvalho et al., 2015). Models of" exact="disease" post="transmission between vectors and humans, as well as vector"/>
  <result pre="in future modeling studies. Data to inform these models is" exact="limited" post="at present; however initial impressions may be gained by"/>
  <result pre="be introduced into the vector population and/or alternative vector and" exact="disease" post="control interventions to be put in place to minimize"/>
  <result pre="To aid in these efforts, accurate rapid assays for pathogen" exact="susceptibility to" post="effector genes will be extremely useful, as will a"/>
  <result pre="epidemiological, what is the desired reduction in clinical incidence of" exact="disease" post="(or some other disease-related measure), and over what time"/>
  <result pre="up to an open release with the intent of wide-scale" exact="disease" post="control, however, an epidemiological endpoint will be of most"/>
  <result pre="timepoints sufficiently after the release to see an effect on" exact="disease" post="incidence. Which TPP we are aiming for dramatically influences"/>
  <result pre="entomological and/or epidemiological endpoints. To be effective in achieving wide-scale" exact="disease" post="control and potentially elimination through reduced pathogen transmission in"/>
  <result pre="the realm of possibility for engineering of disease-refractory effector genes." exact="Combined" post="with monitoring and rapid management of pathogen resistance when"/>
  <result pre="optimistic they will play a pivotal role in eliminating vector-borne" exact="disease" post="transmission on a global scale, in concert with other"/>
  <result pre="Funding This work was supported by funding from the Defense" exact="Advanced" post="Research Project Agency (DARPA) Safe Genes Program Grant (HR0011-17-2-"/>
  <result pre="0047) awarded to O.S.A. and J.M.M. Funds from the UC" exact="Irvine" post="Malaria Initiative supported J.M.M. Conflict of Interest The authors"/>
  <result pre="awarded to O.S.A. and J.M.M. Funds from the UC Irvine" exact="Malaria" post="Initiative supported J.M.M. Conflict of Interest The authors declare"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="virus by Aedes aegypti. Sci. Rep.6, 28792. 10.1038/srep2879227364935 AndinoR.DomingoE. (2015)." exact="Viral" post="quasispecies. Virology479–480. 10.1016/j.virol.2015.03.022 BeaucourtS.VignuzziM. (2014). Ribavirin: a drug active"/>
  <result pre="10.1016/j.coviro.2014.04.01124846716 BeheraA. K.BasuS.CherianS. S. (2015). Molecular mechanism of the enhanced" exact="viral" post="fitness contributed by secondary mutations in the hemagglutinin protein"/>
  <result pre="(2015). Molecular mechanism of the enhanced viral fitness contributed by" exact="secondary" post="mutations in the hemagglutinin protein of oseltamivir resistant H1N1"/>
  <result pre="Gene557, 19–27. 10.1016/j.gene.2014.12.00325479009 BhattS.WeissD. J.CameronE.BisanzioD.MappinB.DalrympleU.et al. (2015). The effect of" exact="malaria" post="control on Plasmodium falciparum in Africa between 2000 and"/>
  <result pre="arbovirus-vector interactions. Viruses7, 820–843. 10.3390/v702082025690800 BloomJ. D.GongL. I.BaltimoreD. (2010). Permissive" exact="secondary" post="mutations enable the evolution of influenza oseltamivir resistance. Science328,"/>
  <result pre="oseltamivir-resistant influenza neuraminidase. PloS One6, e22201. 10.1371/journal.pone.002220121799795 BodenD.PuschO.LeeF.TuckerL.RamratnamB. (2003). Human" exact="Immunodeficiency" post="Virus Type 1 Escape from RNA Interference. J. Virol.77,"/>
  <result pre="neuraminidase. PloS One6, e22201. 10.1371/journal.pone.002220121799795 BodenD.PuschO.LeeF.TuckerL.RamratnamB. (2003). Human Immunodeficiency Virus" exact="Type 1" post="Escape from RNA Interference. J. Virol.77, 11531–11535. 10.1128/JVI.77.21.11531-11535.200314557638 BrackneyD."/>
  <result pre="J. Virol.89, 4035–4039. 10.1128/JVI.02612-1425631077 BraultA. C.PowersA. M.OrtizD.Estrada-FrancoJ. G.Navarro-LopezR.WeaverS. C. (2004)." exact="Venezuelan equine encephalitis" post="emergence: enhanced vector infection from a single amino acid"/>
  <result pre="4035–4039. 10.1128/JVI.02612-1425631077 BraultA. C.PowersA. M.OrtizD.Estrada-FrancoJ. G.Navarro-LopezR.WeaverS. C. (2004). Venezuelan equine" exact="encephalitis" post="emergence: enhanced vector infection from a single amino acid"/>
  <result pre="M.OrtizD.Estrada-FrancoJ. G.Navarro-LopezR.WeaverS. C. (2004). Venezuelan equine encephalitis emergence: enhanced vector" exact="infection" post="from a single amino acid substitution in the envelope"/>
  <result pre="Sci. U. S. A.101, 11344–11349. 10.1073/pnas.040290510115277679 BuchmanA.GamezS.LiM.AntoshechkinI.LeeS.-H.WangS.-W.et al. (2019a). Broad" exact="Dengue" post="Neutralization in Mosquitoes Expressing an Engineered Antibody. SSRN Electron."/>
  <result pre="Sci.116, 3656–3661. 10.1073/pnas.181077111630723148 BurtA.CoulibalyM.CrisantiA.DiabateA.KayondoJ. K. (2018). Gene drive to reduce" exact="malaria" post="transmission in sub-Saharan Africa. J. Responsible Innovation5, S66–S80. 10.1080/23299460.2017.1419410"/>
  <result pre="Carballar-LejarazúR.JamesA. A. (2017). Population modification of Anopheline species to control" exact="malaria" post="transmission. Pathog. Glob. Health111, 424–435. 10.1080/20477724.2018.142719229385893 CarterJ. R.TaylorS.FraserT. S.KucharskiC."/>
  <result pre="R.TaylorS.FraserT. S.KucharskiC. A.DawsonJ. L.FraserM. J. (2015). Suppression of the Arboviruses" exact="Dengue" post="and Chikungunya Using a Dual-Acting Group-I Intron Coupled with"/>
  <result pre="e0003864. 10.1371/journal.pntd.000386426135160 Ceccherini-SilbersteinF.GagoF.SantoroM.GoriC.SvicherV.Rodríguez-BarriosF.et al. (2005). High sequence conservation of human" exact="immunodeficiency" post="virus type 1 reverse transcriptase under drug pressure despite"/>
  <result pre="Ceccherini-SilbersteinF.GagoF.SantoroM.GoriC.SvicherV.Rodríguez-BarriosF.et al. (2005). High sequence conservation of human immunodeficiency virus" exact="type 1" post="reverse transcriptase under drug pressure despite the continuous appearance"/>
  <result pre="resistance in Plasmodium vivax and Plasmodium falciparum isolates from the" exact="Brazilian" post="Amazon and a systematic review of the literature. Malaria"/>
  <result pre="the Brazilian Amazon and a systematic review of the literature." exact="Malaria" post="J.16. 10.1186/s12936-017-1806-z CrottyS.CameronC.AndinoR. (2002). Ribavirin’s antiviral mechanism of action:"/>
  <result pre="A.98, 6895–6900. 10.1073/pnas.11108559811371613 DasA. T.BrummelkampT. R.WesterhoutE. M.VinkM.MadiredjoM.BernardsR.et al. (2004). Human" exact="immunodeficiency" post="virus type 1 escapes from RNA interference-mediated inhibition. J."/>
  <result pre="10.1073/pnas.11108559811371613 DasA. T.BrummelkampT. R.WesterhoutE. M.VinkM.MadiredjoM.BernardsR.et al. (2004). Human immunodeficiency virus" exact="type 1" post="escapes from RNA interference-mediated inhibition. J. Virol.78, 2601–2605. 10.1128/JVI.78.5.2601-2605.200414963165"/>
  <result pre="Drugs65, 75–87. 10.2165/00003495-200565010-00004 DebingY.GisaA.DallmeierK.PischkeS.BremerB.MannsM.et al. (2014). A mutation in the" exact="hepatitis" post="E virus RNA polymerase promotes its replication and associates"/>
  <result pre="Rev. Microbiol.51, 151–178. 10.1146/annurev.micro.51.1.1519343347 DondorpA. M.NostenF.YiP.DasD.PhyoA. P.TarningJ.et al. (2009). Artemisinin" exact="Resistance" post="inPlasmodium falciparumMalaria. N. Engl. J. Med.361, 455–467. 10.1056/NEJMoa080885919641202 DongY.CirimotichC."/>
  <result pre="521–530. 10.1016/j.chom.2012.09.00423084919 DongY.DasS.CirimotichC.Souza-NetoJ. A.McLeanK. J.DimopoulosG. (2011). Engineered anopheles immunity to" exact="Plasmodium infection." post="PloS Pathog.7, e1002458. 10.1371/journal.ppat.100245822216006 DongY.SimõesM. L.MaroisE.DimopoulosG. (2018). CRISPR/Cas9 -mediated"/>
  <result pre="(2018). CRISPR/Cas9 -mediated gene knockout of Anopheles gambiae FREP1 suppresses" exact="malaria" post="parasite infection. PloS Pathogens14, e1006898. 10.1371/journal.ppat.100689829518156 DoudnaJ. A.CharpentierE. (2014)."/>
  <result pre="engineering with CRISPR-Cas9. Science346, 1258096. 10.1126/science.125809625430774 DuruV.WitkowskiB.MénardD. (2016). Plasmodium falciparum" exact="Resistance" post="to Artemisinin Derivatives and Piperaquine: A Major Challenge for"/>
  <result pre="Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for" exact="Malaria" post="Elimination in Cambodia. Am. J. Trop. Med. Hyg.95, 1228–1238."/>
  <result pre="wild populations. Elife3, e03401. 10.7554/eLife.0340125035423 FeachemR. G. A.ChenI.AkbariO.Bertozzi-VillaA.BhattS.BinkaF.et al. (2019)." exact="Malaria" post="eradication within a generation: ambitious, achievable, and necessary. Lancet."/>
  <result pre="2860. 10.1038/s41598-019-38792-430814598 FilomatoriC. V.CarballedaJ. M.VillordoS. M.AguirreS.PallarésH. M.MaestreA. M.et al. (2017)." exact="Dengue" post="virus genomic variation associated with mosquito adaptation defines the"/>
  <result pre="genomic variation associated with mosquito adaptation defines the pattern of" exact="viral" post="non-coding RNAs and fitness in human cells. PloS Pathog.13,"/>
  <result pre="A.et al. (2006). Engineering RNA interference-based resistance to dengue virus" exact="type 2" post="in genetically modified Aedes aegypti. Proc. Natl. Acad. Sci."/>
  <result pre="Dis.8, e2833. 10.1371/journal.pntd.000283324810399 FrentiuF. D.ZakirT.WalkerT.PopoviciJ.PykeA. T.van den HurkA.et al. (2014)." exact="Limited" post="dengue virus replication in field-collected Aedes aegypti mosquitoes infected"/>
  <result pre="Highly efficient Cas9-mediated gene drive for population modification of the" exact="malaria" post="vector mosquito Anopheles stephensi. Proc. Natl. Acad. Sci. U."/>
  <result pre="e4569. 10.1371/journal.pone.000456919238219 GitlinL.StoneJ. K.AndinoR. (2005). Poliovirus escape from RNA interference:" exact="short" post="interfering RNA-target recognition and implications for therapeutic approaches. J."/>
  <result pre="Virol.79, 1027–1035. 10.1128/JVI.79.2.1027-1035.200515613331 GregsonA.PloweC. V. (2005). Mechanisms of resistance of" exact="malaria" post="parasites to antifolates. Pharmacol. Rev.57, 117–145. 10.1124/pr.57.1.415734729 GrubaughN. D.Weger-LucarelliJ.MurrietaR."/>
  <result pre="D.Weger-LucarelliJ.MurrietaR. A.FauverJ. R.Garcia-LunaS. M.PrasadA. N.et al. (2016). Genetic Drift during" exact="Systemic" post="Arbovirus Infection of Mosquito Vectors Leads to Decreased Relative"/>
  <result pre="R.Garcia-LunaS. M.PrasadA. N.et al. (2016). Genetic Drift during Systemic Arbovirus" exact="Infection" post="of Mosquito Vectors Leads to Decreased Relative Fitness during"/>
  <result pre="10.1038/nrmicro.2017.16129355852 HammondA.GaliziR.KyrouK.SimoniA.SiniscalchiC.KatsanosD.et al. (2016). A CRISPR-Cas9 gene drive system targeting" exact="female" post="reproduction in the malaria mosquito vector Anopheles gambiae. Nat."/>
  <result pre="A CRISPR-Cas9 gene drive system targeting female reproduction in the" exact="malaria" post="mosquito vector Anopheles gambiae. Nat. Biotechnol.34, 78–83. 10.1038/nbt.343926641531 HoffmannA."/>
  <result pre="Nature476, 454–457. 10.1038/nature1035621866160 HoffmannA. A.RossP. A.RašićG. (2015). Wolbachia strains for" exact="disease" post="control: ecological and evolutionary considerations. Evol. Appl.8, 751–768. 10.1111/eva.1228626366194"/>
  <result pre="A.Jacobs-LorenaM. (2002). Transgenic anopheline mosquitoes impaired in transmission of a" exact="malaria" post="parasite. Nature417, 452–455. 10.1038/417452a12024215 JamesS.CollinsF. H.WelkhoffP. A.EmersonC.GodfrayH. C. J.GottliebM.et"/>
  <result pre="Drive Mosquitoes as a Potential Biocontrol Tool for Elimination of" exact="Malaria" post="in Sub-Saharan Africa: Recommendations of a Scientific Working Group"/>
  <result pre="E.et al. (2017). Engineered Aedes aegypti JAK/STAT Pathway-Mediated Immunity to" exact="Dengue" post="Virus. PloS Negl. Trop. Dis.11, e0005187. 10.1371/journal.pntd.000518728081143 KilleenG. F.TatarskyA.DiabateA.ChaccourC."/>
  <result pre="O.et al. (2017). Developing an expanded vector control toolbox for" exact="malaria" post="elimination. BMJ Glob Health2, e000211. 10.1136/bmjgh-2016-000211 KiwareS. S.ChitnisN.TatarskyA.WuS.CastellanosH. M."/>
  <result pre="fronts: Insights from the Vector Control Optimization Model (VCOM) for" exact="malaria" post="elimination. PloS One12, e0187680. 10.1371/journal.pone.018768029194440 KoellaJ. C.LynchP. A.ThomasM. B.ReadA."/>
  <result pre="e0187680. 10.1371/journal.pone.018768029194440 KoellaJ. C.LynchP. A.ThomasM. B.ReadA. F. (2009). Towards evolution-proof" exact="malaria" post="control with insecticides. Evol. Appl.2, 469–480. 10.1111/j.1752-4571.2009.00072.x25567892 KohC.AudsleyM. D.Di"/>
  <result pre="K.et al. (2018). A CRISPR-Cas9 gene drive targeting doublesex causes" exact="complete" post="population suppression in caged Anopheles gambiae mosquitoes. Nat. Biotechnol.36,"/>
  <result pre="(2019). Development of a Confinable Gene-Drive System in the Human" exact="Disease" post="Vector, Aedes aegypti. bioRxiv.10.1101/645440 LindseyA.BhattacharyaT.NewtonI.HardyR. (2018). Conflict in the"/>
  <result pre="- Impact of Genetic Modification of Vector Populations on the" exact="Malaria" post="Eradication Agenda,&quot; in Genetic Control of Malaria and Dengue."/>
  <result pre="Populations on the Malaria Eradication Agenda,&quot; in Genetic Control of" exact="Malaria" post="and Dengue. Ed. AdelmanZ. N. (Boston: Academic Press), 423–444."/>
  <result pre="Rep.7, 3776. 10.1038/s41598-017-02744-728630470 MartinR. E.MarchettiR. V.CowanA. I.HowittS. M.BroerS.KirkK. (2009). Chloroquine" exact="Transport" post="via the Malaria Parasite’s Chloroquine Resistance Transporter. Science325, 1680–1682."/>
  <result pre="MartinR. E.MarchettiR. V.CowanA. I.HowittS. M.BroerS.KirkK. (2009). Chloroquine Transport via the" exact="Malaria" post="Parasite’s Chloroquine Resistance Transporter. Science325, 1680–1682. 10.1126/science.117566719779197 MathurG.Sanchez-VargasI.AlvarezD.OlsonK. E.MarinottiO.JamesA."/>
  <result pre="I.HowittS. M.BroerS.KirkK. (2009). Chloroquine Transport via the Malaria Parasite’s Chloroquine" exact="Resistance" post="Transporter. Science325, 1680–1682. 10.1126/science.117566719779197 MathurG.Sanchez-VargasI.AlvarezD.OlsonK. E.MarinottiO.JamesA. A. (2010). Transgene-mediated"/>
  <result pre="suppression of dengue viruses in the salivary glands of the" exact="yellow fever" post="mosquito,Aedes aegypti. Insect Mol. Biol.19, 753–763. 10.1111/j.1365-2583.2010.01032.x20738425 MathurK.AnandA.DubeyS. K.Sanan-MishraN.BhatnagarR."/>
  <result pre="Mol. Biol.19, 753–763. 10.1111/j.1365-2583.2010.01032.x20738425 MathurK.AnandA.DubeyS. K.Sanan-MishraN.BhatnagarR. K.SunilS. (2016). Analysis of" exact="chikungunya" post="virus proteins reveals that non-structural proteins nsP2 and nsP3"/>
  <result pre="Trop. Dis.8, e2994. 10.1371/journal.pntd.000299425058001 Menéndez-AriasL. (2013). Molecular basis of human" exact="immunodeficiency" post="virus type 1 drug resistance: overview and recent developments."/>
  <result pre="e2994. 10.1371/journal.pntd.000299425058001 Menéndez-AriasL. (2013). Molecular basis of human immunodeficiency virus" exact="type 1" post="drug resistance: overview and recent developments. Antiviral Res.98, 93–120."/>
  <result pre="Med. Hyg.77, 365–370. 10.4269/ajtmh.2007.77.36517690414 NishitsujiH.KoharaM.KannagiM.MasudaT. (2006). Effective suppression of human" exact="immunodeficiency" post="virus type 1 through a combination of short- or"/>
  <result pre="365–370. 10.4269/ajtmh.2007.77.36517690414 NishitsujiH.KoharaM.KannagiM.MasudaT. (2006). Effective suppression of human immunodeficiency virus" exact="type 1" post="through a combination of short- or long-hairpin RNAs targeting"/>
  <result pre="NougairedeA.De FabritusL.AubryF.GouldE. A.HolmesE. C.de LamballerieX. (2013). Random codon re-encoding induces" exact="stable" post="reduction of replicative fitness of Chikungunya virus in primate"/>
  <result pre="combination therapies: A sword of Damocles in the path toward" exact="malaria" post="elimination. Parasite25, 24. 10.1051/parasite/201802129676250 PattersonE. I.KhanipovK.RojasM. M.KautzT. F.Rockx-BrouwerD.GolovkoG.et al."/>
  <result pre="10.1051/parasite/201802129676250 PattersonE. I.KhanipovK.RojasM. M.KautzT. F.Rockx-BrouwerD.GolovkoG.et al. (2018). Mosquito bottlenecks alter" exact="viral" post="mutant swarm in a tissue and time-dependent manner with"/>
  <result pre="(3), 1–20. 10.1101/172221 Sánchez-VargasI.ScottJ. C.Katherine Poole-SmithB.FranzA. W. E.Barbosa-SolomieuV.WiluszJ.et al. (2009)." exact="Dengue" post="Virus Type 2 Infections of Aedes aegypti Are Modulated"/>
  <result pre="10.1101/172221 Sánchez-VargasI.ScottJ. C.Katherine Poole-SmithB.FranzA. W. E.Barbosa-SolomieuV.WiluszJ.et al. (2009). Dengue Virus" exact="Type 2" post="Infections of Aedes aegypti Are Modulated by the Mosquito’s"/>
  <result pre="C.Katherine Poole-SmithB.FranzA. W. E.Barbosa-SolomieuV.WiluszJ.et al. (2009). Dengue Virus Type 2" exact="Infections" post="of Aedes aegypti Are Modulated by the Mosquito’s RNA"/>
  <result pre="burden of dengue: an analysis from the Global Burden of" exact="Disease" post="Study 2013. Lancet Infect. Dis.16, 712–723. 10.1016/S1473-3099(16)00026-826874619 SteinhauerD. A.DomingoE.HollandJ."/>
  <result pre="10.1016/j.ibmb.2004.03.01315242701 TsetsarkinK. A.VanlandinghamD. L.McGeeC. E.HiggsS. (2007). A single mutation in" exact="chikungunya" post="virus affects vector specificity and epidemic potential. PloS Pathog.3,"/>
  <result pre="Pathog.7, e1002412. 10.1371/journal.ppat.100241222174678 UncklessR. L.ClarkA. G.MesserP. W. (2017). Evolution of" exact="Resistance" post="Against CRISPR/Cas9 Gene Drive. Genetics205, 827–841. 10.1534/genetics.116.19728527941126 VasilakisN.DeardorffE. R.KenneyJ."/>
  <result pre="Virus Res.107, 173–181. 10.1016/j.virusres.2004.11.00715649563 VillordoS. M.FilomatoriC. V.Sánchez-VargasI.BlairC. D.GamarnikA. V. (2015)." exact="Dengue" post="virus RNA structure specialization facilitates host adaptation. PloS Pathog.11,"/>
  <result pre="the most efficient allocation of interventions to achieve reductions in" exact="Plasmodium falciparum malaria" post="burden and transmission in Africa: a modelling study. Lancet"/>
  <result pre="efficient allocation of interventions to achieve reductions in Plasmodium falciparum" exact="malaria" post="burden and transmission in Africa: a modelling study. Lancet"/>
  <result pre="for malaria. Parasitol. Today12, 399–401. 10.1016/0169-4758(96)10055-715275291 WilsonJ. A.RichardsonC. D. (2005)." exact="Hepatitis" post="C virus replicons escape RNA interference induced by a"/>
  <result pre="Hepatitis C virus replicons escape RNA interference induced by a" exact="short" post="interfering RNA directed against the NS5b coding region. J."/>
  <result pre="Broad-spectrum antiviral activity of RNA interference against four genotypes of" exact="Japanese encephalitis" post="virus based on single microRNA polycistrons. PloS One6, e26304."/>
  <result pre="antiviral activity of RNA interference against four genotypes of Japanese" exact="encephalitis" post="virus based on single microRNA polycistrons. PloS One6, e26304."/>
 </snippets>
</snippetsTree>
